Baseline characteristics of patients in the statin and no-statin groups
| . | Statin group, n (%) (n = 10) . | No-statin group, n (%) (n = 57) . | P . |
|---|---|---|---|
| Median age, y (range) | 50 (27-62) | 42 (20-73) | .72 |
| Sex | .29 | ||
| Male | 4 (40) | 35 (61) | — |
| Female | 6 (60) | 22 (39) | — |
| Stem-cell source | .58 | ||
| PBSC | 10 (100) | 51 (89) | — |
| BM | 0 | 6 (11) | — |
| Donor source | .14 | ||
| HLA-matched sibling | 9 (90) | 36 (63) | — |
| HLA-matched unrelated | 1 (10) | 16 (28) | — |
| HLA-mismatched unrelated | — | 5 (9) | — |
| Diagnosis | .71 | ||
| AML | 8 (80) | 41 (72) | — |
| ALL | 2 (20) | 16 (28) | — |
| Disease risk | .49 | ||
| Standard-risk | 6 (60) | 25 (44) | — |
| High-risk | 4 (40) | 32 (56) | — |
| Myeloablative conditioning | .09 | ||
| Yes | 7 (70) | 52 (91) | — |
| No | 3 (30) | 5 (9) | — |
| GVHD prophylaxis | .39 | ||
| CSA/MTX | 5 (50) | 47 (82) | — |
| FK/MTX | 3 (30) | 10 (18) | — |
| CSA | 2 (20) | — | — |
| Median CD34+ cell dose (106 cells/kg recipient weight) | 5.44 | 4.82 | .73 |
| Median CD3+ cell dose (106 cells/kg recipient weight) | 2.76 | 2.66 | .81 |
| Conditioning regimen | .20 | ||
| TBI/Cy | 2 (20) | 8 (14) | — |
| Bu/Cy | 6 (60) | 33 (58) | — |
| Flu/Bu | 2 (20) | 5 (9) | — |
| Others | — | 11 (19) | — |
| . | Statin group, n (%) (n = 10) . | No-statin group, n (%) (n = 57) . | P . |
|---|---|---|---|
| Median age, y (range) | 50 (27-62) | 42 (20-73) | .72 |
| Sex | .29 | ||
| Male | 4 (40) | 35 (61) | — |
| Female | 6 (60) | 22 (39) | — |
| Stem-cell source | .58 | ||
| PBSC | 10 (100) | 51 (89) | — |
| BM | 0 | 6 (11) | — |
| Donor source | .14 | ||
| HLA-matched sibling | 9 (90) | 36 (63) | — |
| HLA-matched unrelated | 1 (10) | 16 (28) | — |
| HLA-mismatched unrelated | — | 5 (9) | — |
| Diagnosis | .71 | ||
| AML | 8 (80) | 41 (72) | — |
| ALL | 2 (20) | 16 (28) | — |
| Disease risk | .49 | ||
| Standard-risk | 6 (60) | 25 (44) | — |
| High-risk | 4 (40) | 32 (56) | — |
| Myeloablative conditioning | .09 | ||
| Yes | 7 (70) | 52 (91) | — |
| No | 3 (30) | 5 (9) | — |
| GVHD prophylaxis | .39 | ||
| CSA/MTX | 5 (50) | 47 (82) | — |
| FK/MTX | 3 (30) | 10 (18) | — |
| CSA | 2 (20) | — | — |
| Median CD34+ cell dose (106 cells/kg recipient weight) | 5.44 | 4.82 | .73 |
| Median CD3+ cell dose (106 cells/kg recipient weight) | 2.76 | 2.66 | .81 |
| Conditioning regimen | .20 | ||
| TBI/Cy | 2 (20) | 8 (14) | — |
| Bu/Cy | 6 (60) | 33 (58) | — |
| Flu/Bu | 2 (20) | 5 (9) | — |
| Others | — | 11 (19) | — |
BM indicates bone marrow; Bu/Cy, busulfan and cyclophosphamide; CSA, cyclosporine; FK, tacrolimus; Flu/Bu, fludarabine and busulfan; MTX, methotrexate; PBSC, peripheral blood stem cells; TBI/Cy, total body irradiation and cyclophosphamide; and —, not applicable.